425 results on '"Castanheira A"'
Search Results
2. 2146. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam against Enterobacterales causing Bloodstream Infection in US Medical Centers (2020–2022)
3. 2756. Activity of Aztreonam-avibactam and Ceftazidime-avibactam against United States Isolates Producing β-lactamases (2020–2021)
4. 2754. Delafloxacin and Comparator Fluoroquinolone In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)
5. 2173. Activity of Ceftobiprole Against Enterococcus faecalis Clinical Isolates From the United States (2016–2020), Including Those From Difficult-to-Treat Infections
6. 2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
7. 2517. Activity of Sulbactam-durlobactam, Antibacterial Combinations, and Comparators Against a Challenge Set of 66 Acinetobacter baumannii-calcoaceticus Species Complex Isolates
8. 2114. Evaluation of Isavuconazole Activity against Non-fumigatus Aspergillus and cryptic Aspergillus species Causing Invasive Infections Worldwide
9. 1946. In Vitro Activity of Ceftobiprole against Staphylococcus aureus Bacteremia Isolates from the United States (2018–2020)
10. 734. Trend Analysis of Oritavancin and Comparator Agents Activity against Enterococcus Causing Infections in US Medical Centers between 2017–2019 and 2022
11. 2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
12. 2174. Cefiderocol Activity Against Multidrug-resistant and Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus complex Clinical Isolates Causing Infection in United States Hospitals (2020–2022)
13. 2117. In Vitro Antimicrobial Activity of Taurolidine against Candida auris Bloodstream Isolates from Global Sources
14. 2801. Antimicrobial Spectrum of Plazomicin and Other Aminoglycosides against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales When Applying New Breakpoints
15. 2755. Activity of Aztreonam-avibactam and Carbapenem-resistant Enterobacterales (CRE) Isolates Collected in a Six-year Period (2017–2022)
16. 2802. Frequency, Antimicrobial Susceptibility, and Molecular Characterization of Carbapenem-Resistant Enterobacterales Stratified by United States Census Divisions: Results from the INFORM Program (2018-2022)
17. 2162. In Vitro Antimicrobial Activity of Ceftobiprole against Streptococcus pneumoniae Isolates from the United States (2016–2020)
18. 2785. Characterization of Methicillin-resistant Staphylococcus aureus Bloodstream Isolates Recovered from Patients Enrolled in a Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole for Treatment of Bacteremia, Including Infective Endocarditis
19. 1812. Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017–2019 and 2022
20. 568. Evaluation of the VITEK 2 XL Antimicrobial Susceptibility Testing for Non-fermenter Gram-Negative Bacilli: The Importance of Continuing to Monitor AST Systems
21. 1292. Activity of Omadacycline and Comparators Against 876 Bacterial Clinical Isolates from Patients with Bone and Joint Infections in the United States and Europe (2015–2022)
22. 1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
23. 1948. Rise of Candida auris Infections Worldwide and Trends on the Activity of Fosmanogepix and Comparator Agents against C. auris Causing Invasive Infections
24. 2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
25. 1949. Activity of Aztreonam-Avibactam against Enterobacterales Resistant to Recently Approved Beta-Lactamase Inhibitor Combinations Collected Worldwide (ex-US; 2020–2022)
26. 2598. Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2020–2022)
27. 2172. Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Multidrug-resistant Enterobacterales Clinical Isolates from United States Hospitals (2020–2022)
28. Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex
29. In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program
30. Affinity of cefotiam for the alternative penicillin binding protein PBP3SAL used by Salmonella inside host eukaryotic cells
31. Endemicity of Pseudomonas aeruginosa producing IMP-18 and/or VIM-2 MBLs from the high-risk clone ST111 in Central America
32. Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern
33. Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex
34. In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Aurveillance Program
35. Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)
36. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers
37. Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21)
38. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers
39. Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021)
40. Trends of β-Lactamase Occurrence among Escherichia coli and Klebsiella pneumoniae in United States Hospitals during a 5-year period and Activity of Antimicrobial Agents against Isolates Stratified by β-Lactamase Type
41. Affinity of cefotiam for the alternative penicillin binding protein PBP3SAL used by Salmonella inside host eukaryotic cells
42. 645. Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014-2021
43. 124. Activity of Novel b-Lactam/b-Lactamase Inhibitor (BL/BLI) Combinations Against AmpC-Producing Species Collected in United States Hospitals
44. 1692. Ceftibuten-Xeruborbactam: In vitro Potency against Enterobacterales in Comparison with Other Oral Beta-lactams (BL) and Beta-lactamase Inhibitor (BLI) Combinations
45. 1686. Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
46. 1677. In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals
47. 2043. In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type
48. 2044. In Vitro Activity of Omadacycline Against 14,000 Bacterial Isolates from the United States by Infection Type (2020-2021)
49. 1836. Frequency and Antimicrobial Susceptibility of Gram-negative Bacteria Isolated from Patients with Bloodstream Infections in United States (US) Medical Centers (2020-2021)
50. 1685. Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019-2021)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.